Nanozyme‐Assisted Engineered Oncolytic Adenovirus for Improving Intratumoral Immune Deficiency and Enhancing Cancer Immunotherapy
Advanced Materials · 2026-11 · 38 (63)
DOI: 10.1002/adma.75119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 29.09.2026. Verfasst von Yuqing Lv und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Rehabilitation Medicine, Rehabilitation and Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine…. Hauptthemen laut MEDLINE: Adenoviridae, Immunotherapy, Oncolytic Viruses, Neoplasms. Die Arbeit nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Interdisciplinary Research Center of Beijing University of Chemical Technology.
Abstract (Originalsprache)
Oncolytic adenovirus (OA) exhibit tumor‐selective tropism, inducing direct oncolysis while simultaneously potentiating host immune responses against malignancies. However, the poor delivery efficiency of the virus targeting tumors and its limited immune activation capacity severely delays the therapeutic effect. This study proposes a kind of immunomodulator—OAencapsulated with gold nanozyme (AuA), possessing peroxidase‐like (POD) activity, named OA@AuA. This design uses bionic mineralization method for coating OAsurface antigens, delaying their clearance during circulation and thereby increasing viral accumulation at the tumor site. The OA@AuA can consume H 2 O 2 to generate reactive oxygen species (ROS), activate the cGAS‐STING pathway and promote the conversion of M2 macrophages to M1 macrophages. Subsequently, the tumor‐associated antigens and damage‐associated molecular patterns (DAMPs) were released, thus upregulating the expression of calreticulin (CALR) and high mobility group protein B1 (HMGB1), causing immunogenic cell death and activating tumor‐specific cytotoxic T cells to attack tumors, thereby reversing the tumor microenvironment. OA@AuA, as a potent immunomodulator, not only has good biocompatibility, but also breaks the immunosuppressive state in the tumor microenvironment, enhances immune infiltration in the tumor microenvironment, reverses immunosuppressive “cold” tumors into immunostimulatory “hot” tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Rehabilitation Medicine, Rehabilitation and Sports Medicine Research Institute of Zhejiang Province, Department of Rehabilitation Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital…
- Clinical Research Institute, Zhejiang Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, Hangzhou, P…
- College of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang, P. R. China.
- Key Discipline of Zhejiang Province in Public Health and Preventive Medicine (First Class, Category A), Hangzhou Medical College, Hangzhou, Zhejiang, P. R. China.
- Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Organic-Inorganic Composites, Beijing Laboratory of Biomedical Materials, Bionanomaterials & Translational Engineering…
- Beijing Laboratory of Biomedical Materials, Beijing University of Chemical Technology, Beijing, P. R. China.
ORCID-Profile: Tong Ge, Yuxuan Liu, Ketao Jin, Jia Jia Xue, Huiyu Liu, Xiaozhou Mou
Förderung
- National Natural Science Foundation of China
- Interdisciplinary Research Center of Beijing University of Chemical Technology
Zitieren
APA
Lv, Y., Wu, Q., Niu, A., Ge, T., Chen, J., Yu, L., Chen, Y., Liu, Y., Jiao, J., Lei, X., Li, Y., Zeng, Y., Jin, K., Xue, J. J., Liu, H., & Mou, X. (2026). Nanozyme‐Assisted Engineered Oncolytic Adenovirus for Improving Intratumoral Immune Deficiency and Enhancing Cancer Immunotherapy. Advanced Materials, 38(63). https://doi.org/10.1002/adma.75119
Vancouver
Lv Y, Wu Q, Niu A, Ge T, Chen J, Yu L, et al. Nanozyme‐Assisted Engineered Oncolytic Adenovirus for Improving Intratumoral Immune Deficiency and Enhancing Cancer Immunotherapy. Advanced Materials. 2026;38(63). doi:10.1002/adma.75119
BibTeX
@article{Lv2026,
author = {Lv, Yuqing and Wu, Qingyuan and Niu, Aodi and Ge, Tong and Chen, Jianshuang and Yu, Liya and Chen, Yuxuan and Liu, Yuxuan and Jiao, Jiao and Lei, Xingyu and Li, Yangyang and Zeng, Yan and Jin, Ketao and Xue, Jia Jia and Liu, Huiyu and Mou, Xiaozhou},
title = {Nanozyme‐Assisted Engineered Oncolytic Adenovirus for Improving Intratumoral Immune Deficiency and Enhancing Cancer Immunotherapy},
journal = {Advanced Materials},
year = {2026},
volume = {38},
number = {63},
doi = {10.1002/adma.75119}
}
EUVIMED